Ranibizumab + Dexamethasone implant and sham injections
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Visual Impairment
Conditions
Visual Impairment, Macular Edema, Central Retinal Vein Occlusion
Trial Timeline
Aug 1, 2011 → Jan 1, 2014
NCT ID
NCT01396083About Ranibizumab + Dexamethasone implant and sham injections
Ranibizumab + Dexamethasone implant and sham injections is a phase 3 stage product being developed by Novartis for Visual Impairment. The current trial status is completed. This product is registered under clinical trial identifier NCT01396083. Target conditions include Visual Impairment, Macular Edema, Central Retinal Vein Occlusion.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01396083 | Phase 3 | Completed |
Competing Products
13 competing products in Visual Impairment
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| pudexacianinium chloride | Astellas Pharma | Phase 3 | 77 |
| pudexacianinium chloride | Astellas Pharma | Phase 3 | 77 |
| Blink® Tears eye drops + Investigational lipid eye drops | Johnson & Johnson | Phase 1 | 33 |
| Blink® Tears eye drops in a multidose bottle + Preservative-free investigational lubricating eye drops in a Novelia® eyedropper | Johnson & Johnson | Phase 2 | 52 |
| Ranibizumab | Novartis | Phase 3 | 77 |
| Ranibizumab + Aflibercept | Novartis | Approved | 85 |
| Ranibizumab | Novartis | Approved | 85 |
| Ranibizumab 0.5mg + Ranibizumab 0.5 mg + Verteporfin PDT | Novartis | Phase 3 | 77 |
| Sham injections + Ranibizumab 0.5 mg | Novartis | Phase 3 | 77 |
| Ranibizumab + Aflibercept | Novartis | Approved | 85 |
| Intravitreal Lucentis 0.5mg | Novartis | Pre-clinical | 23 |
| ZK200775 + ZK200775 + Sodium Chloride | Bayer | Phase 1 | 30 |
| Aflibercept 8 mg (VEGF Trap-Eye, BAY86-5321) | Bayer | Pre-clinical | 20 |